Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Equity Ratio (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Equity Ratio data on record, last reported at 0.07 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 79.98% year-over-year to 0.07; the TTM value through Sep 2025 reached 0.07, down 79.98%, while the annual FY2024 figure was 0.22, 55.32% down from the prior year.
  • Equity Ratio reached 0.07 in Q3 2025 per SGMO's latest filing, down from 0.2 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.76 in Q1 2023 and bottomed at 0.06 in Q1 2025.
  • Average Equity Ratio over 5 years is 0.44, with a median of 0.52 recorded in 2022.
  • Peak YoY movement for Equity Ratio: soared 49.0% in 2023, then tumbled 87.05% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.52 in 2021, then grew by 0.85% to 0.52 in 2022, then fell by 4.38% to 0.5 in 2023, then tumbled by 55.32% to 0.22 in 2024, then plummeted by 68.56% to 0.07 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.07 in Q3 2025, 0.2 in Q2 2025, and 0.06 in Q1 2025.